

# Aneliya Ilieva Parvanova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9844593/publications.pdf>

Version: 2024-02-01

27  
papers

2,245  
citations

471509

17  
h-index

580821

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2864  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.  | 2.5  | 2         |
| 2  | Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109804.   | 2.8  | 10        |
| 3  | FC003: Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Hyperfiltration In Subjects with Prediabetes and Abdominal Obesity Without Evidence of Chronic Kidney Disease. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .   | 0.7  | 0         |
| 4  | MO446: The Prevalence of Mafld in Subjects With Normoglycaemia, Prediabetes and Type 2 Diabetes Without Evidence of Chronic Kidney Disease and its Association With Glomerular Hyperfiltration. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .  | 0.7  | 0         |
| 5  | Preventing microalbuminuria with benazepril, valsartan, and benazeprilâ€“valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021, 18, e1003691.                                 | 8.4  | 7         |
| 6  | Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 301-312.          | 11.4 | 166       |
| 7  | Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. <i>Frontiers in Genetics</i> , 2019, 10, 681.   | 2.3  | 11        |
| 8  | Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.   | 4.4  | 14        |
| 9  | Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 420-436.   | 0.2  | 25        |
| 10 | Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 27-40.  | 11.4 | 24        |
| 11 | Sa0006 INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i317-i317.  | 0.7  | 2         |
| 12 | Characteristics of highâ€“and lowâ€“risk individuals in the <sc>PRIORITY</sc> study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes. <i>Diabetic Medicine</i> , 2018, 35, 1375-1382.  | 2.3  | 24        |
| 13 | Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. <i>Diabetes</i> , 2017, 66, 75-86.  | 0.6  | 66        |
| 14 | The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. <i>Kidney International</i> , 2013, 84, 164-173.  | 5.2  | 131       |
| 15 | Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 19-27. | 11.4 | 37        |
| 16 | ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. <i>Diabetes</i> , 2013, 62, 3599-3609.   | 0.6  | 25        |
| 17 | Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1717-1724.   | 6.1  | 80        |
| 18 | Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2061-2068.  | 8.6  | 259       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.  | 2.7  | 86        |
| 20 | Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1954-1956.                                       | 8.6  | 29        |
| 21 | Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.  | 2.7  | 39        |
| 22 | Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 1629-1634.   | 8.6  | 33        |
| 23 | Insulin Resistance and Microalbuminuria. Diabetes, 2006, 55, 1456-1462.  | 0.6  | 169       |
| 24 | Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Expert Opinion on Pharmacotherapy, 2005, 6, 1931-1942.                  | 1.8  | 4         |
| 25 | Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.   | 27.0 | 952       |
| 26 | Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4371-4376. | 3.6  | 42        |
| 27 | Hyperhomocysteinemia and Increased Risk of Retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. Diabetes Care, 2002, 25, 2361-2361.                                  | 8.6  | 8         |